Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2016

Open Access 01-12-2016 | Research

Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century

Authors: Dianne Pulte, Felipe A. Castro, Lina Jansen, Sabine Luttmann, Bernd Holleczek, Alice Nennecke, Meike Ressing, Alexander Katalinic, Hermann Brenner, GEKID Cancer Survival Working Group

Published in: Journal of Hematology & Oncology | Issue 1/2016

Login to get access

Abstract

Background

Recent population-based studies in the United States of America (USA) and other countries have shown improvements in survival for patients with chronic lymphocytic leukemia (CLL) diagnosed in the early twenty-first century. Here, we examine the survival for patients diagnosed with CLL in Germany in 1997–2011.

Methods

Data were extracted from 12 cancer registries in Germany and compared to the data from the USA. Period analysis was used to estimate 5- and 10-year relative survival (RS).

Results

Five- and 10-year RS estimates in 2009–2011 of 80.2 and 59.5 %, respectively, in Germany and 82.4 and 64.7 %, respectively, in the USA were observed. Overall, 5-year RS increased significantly in Germany and the difference compared to the survival in the USA which slightly decreased between 2003–2005 and 2009–2011. However, age-specific analyses showed persistently higher survival for all ages except for 15–44 in the USA. In general, survival decreased with age, but the age-related disparity was small for patients younger than 75. In both countries, 5-year RS was >80 % for patients less than 75 years of age but <70 % for those age 75+.

Conclusions

Overall, 5-year survival for patients with CLL is good, but 10-year survival is significantly lower, and survival was much lower for those age 75+. Major differences in survival between countries were not observed. Further research into ways to increase survival for older CLL patients are needed to reduce the persistent large age-related survival disparity.
Literature
1.
go back to reference Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymhocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRefPubMedPubMedCentral Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymhocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446–56.CrossRefPubMedPubMedCentral
2.
go back to reference Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99(6):956–72.CrossRef Ghia P, Hallek M. Management of chronic lymphocytic leukemia. Haematologica. 2014;99(6):956–72.CrossRef
3.
go back to reference Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916–21.CrossRefPubMed Brenner H, Gondos A, Pulte D. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood. 2008;111(10):4916–21.CrossRefPubMed
4.
go back to reference Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project. Haematologica. 2011;96(5):720–8.CrossRefPubMedPubMedCentral Marcos-Gragera R, Allemani C, Tereanu C, et al. Survival of European patients diagnosed with lymphoid neoplasms in 2000–2002: results of the HAEMACARE project. Haematologica. 2011;96(5):720–8.CrossRefPubMedPubMedCentral
5.
go back to reference Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer. 2013;132(10):2378–87.CrossRefPubMed Monnereau A, Troussard X, Belot A, et al. Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France. Int J Cancer. 2013;132(10):2378–87.CrossRefPubMed
6.
go back to reference van den Broek EC, Kater AP, van de Schans SA. Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer. 2012;48(6):889–95.CrossRefPubMed van den Broek EC, Kater AP, van de Schans SA. Chronic lymphocytic leukaemia in the Netherlands: trends in incidence, treatment and survival, 1989–2008. Eur J Cancer. 2012;48(6):889–95.CrossRefPubMed
7.
go back to reference Nennecke A, Wienecke A, Kraywinkel K. Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsbl. 2013;57:93–102.CrossRef Nennecke A, Wienecke A, Kraywinkel K. Leukemia incidence and survival in Germany according to current standardized categories. Bundesgesundheitsbl. 2013;57:93–102.CrossRef
8.
go back to reference De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;15(5):2254–68.CrossRef De Angelis R, Minicozzi P, Sant M, et al. Survival variations by country and age for lymphoid and myeloid malignancies in Europe 2000–2007: results of EUROCARE-5 population-based study. Eur J Cancer. 2015;15(5):2254–68.CrossRef
9.
go back to reference Hiripi E, Gondos A, Emrich K, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol. 2012;23(2):472–9.CrossRefPubMed Hiripi E, Gondos A, Emrich K, et al. Survival from common and rare cancers in Germany in the early 21st century. Ann Oncol. 2012;23(2):472–9.CrossRefPubMed
10.
go back to reference Jansen L, Castro FA, Gondos A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015;136(11):2649–58.CrossRefPubMed Jansen L, Castro FA, Gondos A, et al. Recent cancer survival in Germany: an analysis of common and less common cancers. Int J Cancer. 2015;136(11):2649–58.CrossRefPubMed
11.
go back to reference Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research data (1973–2011), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission. Surveillance, Epidemiology, and End Results (SEER) Program (www.​seer.​cancer.​gov) Research data (1973–2011), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2014, based on the November 2013 submission.
12.
go back to reference Mariotto A, Capocaccia R, Verdecchia A, et al. Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control. 2002;13:101–11.CrossRefPubMed Mariotto A, Capocaccia R, Verdecchia A, et al. Projecting SEER cancer survival rates to the US: an ecological regression approach. Cancer Causes Control. 2002;13:101–11.CrossRefPubMed
13.
go back to reference Brenner H, Gefeller O, Hakulinen T. Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Eur J Cancer. 2004;40:326–35.CrossRefPubMed Brenner H, Gefeller O, Hakulinen T. Period analysis for up-to-date cancer survival data: theory, empirical evaluation, computational realization and applications. Eur J Cancer. 2004;40:326–35.CrossRefPubMed
14.
go back to reference Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20:826–32.CrossRefPubMed Brenner H, Hakulinen T. Up-to-date long-term survival curves of patients with cancer by period analysis. J Clin Oncol. 2002;20:826–32.CrossRefPubMed
15.
go back to reference Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardizing survival ratios. Eur J Cancer. 2004;40:2307–16.CrossRefPubMed Corazziari I, Quinn M, Capocaccia R. Standard cancer patient population for age standardizing survival ratios. Eur J Cancer. 2004;40:2307–16.CrossRefPubMed
16.
go back to reference Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Bethesda: National Cancer Institute; 1959. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Bethesda: National Cancer Institute; 1959.
18.
go back to reference Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164(7):689–96.CrossRefPubMed Brenner H, Hakulinen T. Up-to-date and precise estimates of cancer patient survival: model-based period analysis. Am J Epidemiol. 2006;164(7):689–96.CrossRefPubMed
19.
go back to reference Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patients survival. Eur J Cancer. 2002;38:690–5.CrossRefPubMed Brenner H, Gefeller O, Hakulinen T. A computer program for period analysis of cancer patients survival. Eur J Cancer. 2002;38:690–5.CrossRefPubMed
20.
21.
go back to reference Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden. Haematologica. 2009;94(9):1259–65.CrossRefPubMedPubMedCentral Kristinsson SY, Dickman PW, Wilson WH, Caporaso N, Björkholm M, Landgren O. Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden. Haematologica. 2009;94(9):1259–65.CrossRefPubMedPubMedCentral
22.
go back to reference Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clínic of Barcelona experience. Blood. 2009;114(10):2044–50.CrossRefPubMed Abrisqueta P, Pereira A, Rozman C, et al. Improving survival in patients with chronic lymphocytic leukemia (1980–2008): the Hospital Clínic of Barcelona experience. Blood. 2009;114(10):2044–50.CrossRefPubMed
23.
go back to reference Shvidel L, Braester A, Bairey O, et al. Survival trends among 1325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. Am J Hematol. 2011;86(12):985–92.CrossRefPubMed Shvidel L, Braester A, Bairey O, et al. Survival trends among 1325 patients with chronic lymphocytic leukemia seen over the past 40 years in Israel. Am J Hematol. 2011;86(12):985–92.CrossRefPubMed
24.
go back to reference Nabhan C, Rosen S. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312(21):2665–76.CrossRef Nabhan C, Rosen S. Chronic lymphocytic leukemia: a clinical review. JAMA. 2014;312(21):2665–76.CrossRef
25.
go back to reference Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program. 2006:279–84. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program. 2006:279–84.
26.
go back to reference Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. UnmutatedIgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:848–54. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. UnmutatedIgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:848–54.
27.
go back to reference Damle RN, Wasil T, Fais F, et al. IgVH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymhocytic leukemia. Blood. 1999;94:1840–7.PubMed Damle RN, Wasil T, Fais F, et al. IgVH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymhocytic leukemia. Blood. 1999;94:1840–7.PubMed
28.
go back to reference Rosenwald A, ALizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–47.CrossRefPubMedPubMedCentral Rosenwald A, ALizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med. 2001;194:1639–47.CrossRefPubMedPubMedCentral
29.
go back to reference Doehner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.CrossRef Doehner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910–6.CrossRef
30.
go back to reference Chuang HY, Rassenti L, Salcedo M, et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012;120(13):2639–49.CrossRefPubMedPubMedCentral Chuang HY, Rassenti L, Salcedo M, et al. Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. Blood. 2012;120(13):2639–49.CrossRefPubMedPubMedCentral
31.
go back to reference Pulte D, Furman RR, Broekman MJ, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(4):367–72.CrossRefPubMedPubMedCentral Pulte D, Furman RR, Broekman MJ, et al. CD39 expression on T lymphocytes correlates with severity of disease in patients with chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2011;11(4):367–72.CrossRefPubMedPubMedCentral
32.
go back to reference Nwabo Kamdje AH, Bassi G, Pacelli L, et al. Role of stromal cell-mediated Notch signalling in CLL resistance to chemotherapy. Blood Cancer J. 2012;2(5):e73.CrossRefPubMed Nwabo Kamdje AH, Bassi G, Pacelli L, et al. Role of stromal cell-mediated Notch signalling in CLL resistance to chemotherapy. Blood Cancer J. 2012;2(5):e73.CrossRefPubMed
33.
go back to reference Rai KR, Peterson BL, Applebaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750–7.CrossRefPubMed Rai KR, Peterson BL, Applebaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343(24):1750–7.CrossRefPubMed
34.
go back to reference Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2004;45(11):2239–45.CrossRefPubMed Zhu Q, Tan DC, Samuel M, Chan ES, Linn YC. Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia. Leuk Lymphoma. 2004;45(11):2239–45.CrossRefPubMed
35.
go back to reference Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.CrossRefPubMed Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.CrossRefPubMed
36.
go back to reference Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2012;30(26):3209–16.CrossRefPubMed Fischer K, Cramer P, Busch R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol. 2012;30(26):3209–16.CrossRefPubMed
37.
go back to reference Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) shows superior efficacy in comparison to bendamustine and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia: final analysis of an international, randomized study of the German CLL Study Group. Blood. 2014;124(21):19. Eichhorst B, Fink AM, Busch R, et al. Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab (FCR) shows superior efficacy in comparison to bendamustine and rituximab (BR) in previously untreated and physically fit patients with advanced chronic lymphocytic leukemia: final analysis of an international, randomized study of the German CLL Study Group. Blood. 2014;124(21):19.
38.
39.
go back to reference Byrd JC, Brown JR, Barrientos JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRefPubMedPubMedCentral Byrd JC, Brown JR, Barrientos JC, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.CrossRefPubMedPubMedCentral
40.
go back to reference Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015;8:85.CrossRefPubMedPubMedCentral Rai KR. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015;8:85.CrossRefPubMedPubMedCentral
41.
go back to reference Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389–96.CrossRefPubMedPubMedCentral Gribben JG, Zahrieh D, Stephans K, et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005;106(13):4389–96.CrossRefPubMedPubMedCentral
42.
go back to reference Pulte D, Gondos A, Redaniel MT, Brenner H. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011;16(5):663–71.CrossRefPubMedPubMedCentral Pulte D, Gondos A, Redaniel MT, Brenner H. Survival of patients with chronic myelocytic leukemia: comparisons of estimates from clinical trial settings and population-based cancer registries. Oncologist. 2011;16(5):663–71.CrossRefPubMedPubMedCentral
43.
go back to reference Brenner H, Holleczek B. Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificate only. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2480–6.CrossRefPubMed Brenner H, Holleczek B. Deriving valid population-based cancer survival estimates in the presence of nonnegligible proportions of cancers notified by death certificate only. Cancer Epidemiol Biomarkers Prev. 2011;20(12):2480–6.CrossRefPubMed
44.
go back to reference Berrino F, Esteve J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995;132:1–14. Berrino F, Esteve J, Coleman MP. Basic issues in estimating and comparing the survival of cancer patients. IARC Sci Publ. 1995;132:1–14.
Metadata
Title
Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century
Authors
Dianne Pulte
Felipe A. Castro
Lina Jansen
Sabine Luttmann
Bernd Holleczek
Alice Nennecke
Meike Ressing
Alexander Katalinic
Hermann Brenner
GEKID Cancer Survival Working Group
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2016
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-016-0257-2

Other articles of this Issue 1/2016

Journal of Hematology & Oncology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine